1-Tert-butyl-3-methoxy-3-methylazetidine | 1331739-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 1-Tert-butyl-3-methoxy-3-methylazetidine
• 英文别名: 1-tert-butyl-3-methoxy-3-methylazetidine
• CAS: 1331739-25-3
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: NIZJHJUMSSBPHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,3-dibromo-N-(tert-butyl)-2-methylpropan-1-amine 以 异丙醇 为溶剂， 反应 16.0h， 生成 1-Tert-butyl-3-methoxy-3-methylazetidine
  参考文献：
  名称：

  Synthesis of 3-functionalized 3-methylazetidines

  摘要：

  1-t-Butyl- and 1-(4-methylbenzyl)-3-bromo-3-methylazetidines were prepared from the corresponding N-(2,3-dibromo-2-methylpropylidene)alkylamines and their propensity to undergo nucleophilic substitution at the 3-position by different nucleophiles was assessed, providing a convenient access to novel 3-alkoxy-, 3-aryloxy-, 3-hydroxy-, 3-cyano-, 3-carboxy-, 3-(aminomethyl)- and 3-(hydroxymethyl)azetidines. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.10.097

文献信息

• Synthesis and reactivity of non-activated 2-(chloromethyl)aziridines
  作者：Sonja Stanković、Matthias D’hooghe、Jo Dewulf、Piet Bogaert、Robrecht Jolie、Norbert De Kimpe

  DOI：10.1016/j.tetlet.2011.06.062

  日期：2011.8

  efficient synthesis of non-activated 2-(chloromethyl)aziridines and 2-chloromethyl-2-methylaziridines as new representatives of the class of 2-(halomethyl)aziridines was developed. Furthermore, the reactivity of these azaheterocycles was assessed and compared to that of their brominated counterparts, pointing to a similar profile for 2-(chloromethyl)aziridines and 2-(bromomethyl)aziridines on the one

  开发了有效合成的非活化的2-（氯甲基）氮丙啶和2-氯甲基-2-甲基氮丙啶作为2-（卤甲基）氮丙啶类的新代表。此外，评估了这些氮杂杂环的反应性，并将其与溴代对应物进行了比较，一方面表明2-（氯甲基）氮丙啶和2-（溴甲基）氮丙啶的分布相似，但2-氯甲基的行为不同另一方面，关于它们对环扩展成氮杂环丁烷的适应性，-2-甲基氮丙啶对2-溴甲基-2-甲基氮丙啶。
• Biheteroaryl compounds and uses thereof
  申请人：Genentech, Inc.

  公开号：US11129832B2

  公开（公告）日：2021-09-28

  The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.

  本发明提供了用于治疗疾病（如神经退行性疾病）的式-I-I化合物及其实施方案和盐。式-I-I中的R1、R2、R3、X1、X2、A和Cy变量均具有本文所定义的含义。
• PIPERIDINE-DIONE DERIVATIVES
  申请人：Genentech, Inc.

  公开号：US20170001990A1

  公开（公告）日：2017-01-05

  The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A 1 , A 2 , A 3 , A 4 , R 1 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein, compositions including the compounds and methods of using the compounds.
• BENZOFURAN ANALOGUE AS NS4B INHIBITOR
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170240519A1

  公开（公告）日：2017-08-24

  Provided is a benzofuran analogue having a structure represented by formula (I) and used as an NS4B inhibitor, or a pharmaceutically acceptable salt of the benzofuran analogue. The benzofuran analogue has anti-hepatitis C virus activity.
• BIHETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20200188397A1

  公开（公告）日：2020-06-18

  The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R 1 , R 2 , R 3 , X 1 , X 2 , A and Cy variable in Formula I-I all have the meaning as defined herein.